Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Sara Corr

Internal Medicine Denver, CO Medical Doctor

NPI 1942435680 CMS profile 133244

311 Steele St, Denver, CO 80206

Open in the dashboard

General payments

$1,648

115 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Sara Corr of Denver, CO is reported in the CMS Open Payments database as having received $1,648 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $31 2
2021 General $23 1
2020 General $33 2
2019 General $1,561 110

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Corr
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sara Corr were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sara Corr Internal Medicine median Middle half National median
2019 $1,561 $159 $48–$570 $163
2020 $33 $119 $33–$402 $114
2021 $23 $135 $37–$521 $132
2022 $31 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $160 11 payments
  2. Novo Nordisk Inc $137 9 payments
  3. Lilly USA, LLC $137 14 payments
  4. GlaxoSmithKline, LLC. $127 8 payments
  5. Janssen Pharmaceuticals, Inc $125 9 payments
  6. E.R. Squibb & Sons, L.L.C. $96 7 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $93 6 payments
  8. AbbVie, Inc. $93 5 payments
  9. Amgen Inc. $85 6 payments
  10. Astellas Pharma US Inc $77 5 payments
  11. Other $519 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,613 112 payments
  2. Education $35 3 payments
Products named General payments · program years 2019–2022
  1. XARELTO $125 9 payments
  2. INVOKANA $110 8 payments
  3. ELIQUIS $96 7 payments
  4. TRELEGY ELLIPTA $94 6 payments
  5. MYRBETRIQ $77 5 payments
  6. SYMBICORT $75 5 payments
  7. EMGALITY $70 6 payments
  8. ENTRESTO $66 4 payments
  9. ANORO $61 4 payments
  10. TRULICITY $58 7 payments
  11. Other $1,304 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 95 drugs

Part D claims

5,048

Median for Internal Medicine: 777

Drug cost

$516,099

Median for Internal Medicine: $73,373

Branded share of claims

18.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 98 $122,806
Xarelto Rivaroxaban Brand 42 $64,667
Trulicity Dulaglutide Brand 39 $62,913
Mounjaro Tirzepatide Brand 54 $58,937
Ozempic Semaglutide Brand 37 $55,172
Jardiance Empagliflozin Brand 21 $34,590
Myrbetriq Mirabegron Brand 28 $31,521
Belsomra Suvorexant Brand 19 $11,424
Synthroid Levothyroxine Sodium Brand 105 $7,693
Atorvastatin Calcium Generic 472 $4,487

The 10 drugs with the highest cost, of 95 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$81,397

Of which drugs: $22,182

Medicare patients

363

Average age 75

Services billed

1,730

255 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 56%
Arthritis 52%
Osteoporosis 28%
Depression 25%
Ischemic heart disease 22%
Cancer 22%
Diabetes 17%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 86 97 $13,111
Pcv20 vaccine im 90677 Office 15 15 $4,344
Vaccine for influenza for injection into muscle 90662 Office 53 53 $4,336

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record